Resistance to Ibritumomab in Lymphoma (Resistance to Targeted Anti-Cancer Therapeutics, 18, Band 18) - Hardcover

 
9783319782379: Resistance to Ibritumomab in Lymphoma (Resistance to Targeted Anti-Cancer Therapeutics, 18, Band 18)
Hardcover
ISBN 10: 3319782371 ISBN 13: 9783319782379
Verlag: Springer, 2018

Inhaltsangabe

This volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming resistance and enhancing efficacy of ibritumomab.

Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.

Über die Autorin bzw. den Autor

Makoto Hosono, MD, PhD, is a Professor of Radiology and Nuclear Medicine, Institute of Advanced Clinical Medicine, Kindai University Faculty of Medicine, Japan, and serves as a member of Committee 3, International Commission on Radiological Protection. 


Jean-François Chatal, MD, PhD, is an Emeritus Professor of Nuclear Medicine at the University of Nantes, France. He is one of the international leaders who developed radioimmunotherapy, that is, therapy using radiolabeled anti-tumor antibodies. He created and headed an INSERM  research laboratory and also initiated the installation of a cyclotron institute termed ARRONAX for the production of novel radionuclides for nuclear medicine.

Von der hinteren Coverseite

This volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming resistance and enhancing efficacy of ibritumomab.

„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.

Verlag
Springer
Erscheinungsdatum
2018
Sprache
Englisch
ISBN 10 
3319782371
ISBN 13 
9783319782379
Einband
Gebundene Ausgabe
Auflage
1
Anzahl der Seiten
171
Herausgeber
Hosono Makoto, Chatal Jean-François
Kontakt zum Hersteller
ProductSafety@springernature.com
ProductSafety@springernature.com

Poststr. 9
Darmstadt
64293
Deutschland

Weitere beliebte Ausgaben desselben Titels

9783030086527: Resistance to Ibritumomab in Lymphoma (Resistance to Targeted Anti-Cancer Therapeutics, Band 18)

Vorgestellte Ausgabe

ISBN 10:  3030086526 ISBN 13:  9783030086527
Verlag: Springer, 2019
Softcover